Overview

MannKind Corporation (Nasdaq:MNKD) is a biopharmaceutical company that focuses on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Our lead investigational product candidate, AFREZZA® , is an ultra rapid-acting insulin. AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes for the control of hyperglycemia.

Featured Links


Receive E-mail AlertsE-mail Alert Icon
Alerts are e-mailed to you whenever certain new company information is posted to this site.
Sign-up Now!
MNKD (Common Stock)
ExchangeNASDAQ GM (US Dollar)
Price$6.38
Change (%) Stock is Up 0.02 (0.31%)
Volume5,004,034
Data as of 04/24/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore Press Releases
DateTitle 
04/07/14MannKind Updates Status of New Drug Application for AFREZZA(R)
VALENCIA, Calif., April 7, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA® by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA's requests. About AFREZZA® AFREZZA® (uh-FREZZ-uh) is a novel, ultra rapid-acting mealtime insulin therapy developed by MannKind Co... 
Printer Friendly Version
04/01/14FDA Advisory Committee Recommends Approval of AFREZZA(R), MannKind Corporation's Investigational Drug to Treat Diabetes
VALENCIA, Calif., April 1, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) voted 13 to 1 to recommend that AFREZZA® (insulin human [rDNA origin]) Inhalation Powder be granted marketing approval by the FDA to improve glycemic control in adults with type 1 diabetes and voted 14 to 0 to recommend that AFREZZA be granted marketing approval by the FDA to improve gl... 
Printer Friendly Version
02/19/14MannKind Corporation to Present at Upcoming Conferences
VALENCIA, Calif., Feb. 19, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on discovering, developing and commercializing treatments for diabetes, announced today that it will present at upcoming conferences. The RBC Capital Markets 2014 Global Healthcare Conference on February 25, 2014 at 11:30 AM (ET) at The New York Palace in New York, New York.   Cowen and Company 34th Annual Health Care Conference on March 3, 2014 at 3:30 PM (ET) at the Boston Marriott Copley i... 
Printer Friendly Version
02/18/14MannKind Corporation Reports 2013 Fourth Quarter and Full Year Financial Results
Conference Call to Begin Today at 5:00 PM ET VALENCIA, Calif., Feb. 18, 2014 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today reported financial results for the fourth quarter and full year ended December 31, 2013. For the fourth quarter of 2013, total operating expenses were $46.6 million, compared to $33.5 million for the fourth quarter of 2012, an increase of $13.1 million. Research and development (R&D) expenses were $29.0 million for the fourth quarter of 2013, compared... 
Printer Friendly Version
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.



Print Page Print | E-mail Page E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Tear Sheet